OptiBiotix Health Plc, a life sciences company, (OPTI) Fair Value & Analysis
Healthcare · GB · Market cap 6.5M GBX
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from £0.0100 to £0.0295 (+195.3%) since Jun 25, 2026. Share price +1.6% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.0485 – £0.1300 · the £0.0635 price screens above the £0.0295 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
OptiBiotix Health Plc, a life sciences company, (OPTI) currently trades at £0.0635, while our model-based Fair Value estimate is £0.0295 — implying the stock looks roughly 53.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, OptiBiotix Health Plc, a life sciences company, generated revenue of £1.2M at a net margin of -16.6%. Revenue grew 101.8% year over year. It earns a return on equity of -2.4%. The balance sheet holds a net cash position of £1.0M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its first-generation products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; and WellBiome a novel in vitro model of the human gut. In addition, the company offers second-generation solutions, including Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners; and Microbiome Modulators. Further, it provides CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; OptiBiotics, a portfolio of prebiotics developed to target…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
OptiBiotix Health Plc, a life sciences company, reported revenue of £1.2M in FY2025 versus £2.2M in FY2021, a compound −14.8%/yr. Reported net income was −£3.9M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is OptiBiotix Health Plc, a life sciences company, (OPTI) undervalued?
What is the fair value of OPTI?
What is the quality score of OPTI?
What is the revenue of OptiBiotix Health Plc, a life sciences company, (OPTI)?
What is the net profit margin of OPTI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.